CD7+, CD4-, CD8- acute leukemia: A syndrome of malignant pluripotent lymphohematopoietic cells

J. Kurtzberg, T. A. Waldmann, Michael Davey, S. H. Bigner, J. O. Moore, M. S. Hershfield, B. F. Haynes

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Following our initial observation of in vivo conversion of CD7+, CD4-, CD8- acute lymphoblastic leukemia (ALL) cells from lymphoid to myeloid lineages (Proc Natl Acad Sci (USA) 81:253, 1984) we have studied eight additional cases of ALL with this leukemic cell phenotype. The CD7+, CD4-, CD8- phenotype was associated with a distinct clinical entity with those affected predominately male (either 65 years of age), with frequent mediastinal and/or thymic masses, skin and CNS disease, high peripheral WBC counts, and bone marrow blasts that were morphologically L1 or not ascribable to a specific lineage. These patients did not respond to conventional chemotherapeutic regimens for either acute lymphoid or myeloid leukemias. No common karyotype or T-cell gene rearrangement pattern could be defined. Importantly, seven of eight patients' leukemic cells studied were capable of multilineage (myeloid, erythroid, monocytoid, megakaryocytoid, and lymphoid) differentiation in vitro. Data is presented suggesting that CD7+, CD4-, CD8- leukemias, in many instances, are leukemias of immature hematopoietic cells. The development of novel therapeutic approaches to this form of leukemia will be necessary to alter its poor prognosis.

Original languageEnglish (US)
Pages (from-to)381-390
Number of pages10
JournalBlood
Volume73
Issue number2
StatePublished - 1989
Externally publishedYes

Fingerprint

T-cells
Skin
Bone
Leukemia
Genes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
T-Lymphocyte Gene Rearrangement
Phenotype
Lymphoid Leukemia
Central Nervous System Diseases
Karyotype
Skin Diseases
Bone Marrow
Observation
Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Kurtzberg, J., Waldmann, T. A., Davey, M., Bigner, S. H., Moore, J. O., Hershfield, M. S., & Haynes, B. F. (1989). CD7+, CD4-, CD8- acute leukemia: A syndrome of malignant pluripotent lymphohematopoietic cells. Blood, 73(2), 381-390.

CD7+, CD4-, CD8- acute leukemia : A syndrome of malignant pluripotent lymphohematopoietic cells. / Kurtzberg, J.; Waldmann, T. A.; Davey, Michael; Bigner, S. H.; Moore, J. O.; Hershfield, M. S.; Haynes, B. F.

In: Blood, Vol. 73, No. 2, 1989, p. 381-390.

Research output: Contribution to journalArticle

Kurtzberg, J, Waldmann, TA, Davey, M, Bigner, SH, Moore, JO, Hershfield, MS & Haynes, BF 1989, 'CD7+, CD4-, CD8- acute leukemia: A syndrome of malignant pluripotent lymphohematopoietic cells', Blood, vol. 73, no. 2, pp. 381-390.
Kurtzberg J, Waldmann TA, Davey M, Bigner SH, Moore JO, Hershfield MS et al. CD7+, CD4-, CD8- acute leukemia: A syndrome of malignant pluripotent lymphohematopoietic cells. Blood. 1989;73(2):381-390.
Kurtzberg, J. ; Waldmann, T. A. ; Davey, Michael ; Bigner, S. H. ; Moore, J. O. ; Hershfield, M. S. ; Haynes, B. F. / CD7+, CD4-, CD8- acute leukemia : A syndrome of malignant pluripotent lymphohematopoietic cells. In: Blood. 1989 ; Vol. 73, No. 2. pp. 381-390.
@article{e02fbc9d923f4eacabd279ad0509c051,
title = "CD7+, CD4-, CD8- acute leukemia: A syndrome of malignant pluripotent lymphohematopoietic cells",
abstract = "Following our initial observation of in vivo conversion of CD7+, CD4-, CD8- acute lymphoblastic leukemia (ALL) cells from lymphoid to myeloid lineages (Proc Natl Acad Sci (USA) 81:253, 1984) we have studied eight additional cases of ALL with this leukemic cell phenotype. The CD7+, CD4-, CD8- phenotype was associated with a distinct clinical entity with those affected predominately male (either 65 years of age), with frequent mediastinal and/or thymic masses, skin and CNS disease, high peripheral WBC counts, and bone marrow blasts that were morphologically L1 or not ascribable to a specific lineage. These patients did not respond to conventional chemotherapeutic regimens for either acute lymphoid or myeloid leukemias. No common karyotype or T-cell gene rearrangement pattern could be defined. Importantly, seven of eight patients' leukemic cells studied were capable of multilineage (myeloid, erythroid, monocytoid, megakaryocytoid, and lymphoid) differentiation in vitro. Data is presented suggesting that CD7+, CD4-, CD8- leukemias, in many instances, are leukemias of immature hematopoietic cells. The development of novel therapeutic approaches to this form of leukemia will be necessary to alter its poor prognosis.",
author = "J. Kurtzberg and Waldmann, {T. A.} and Michael Davey and Bigner, {S. H.} and Moore, {J. O.} and Hershfield, {M. S.} and Haynes, {B. F.}",
year = "1989",
language = "English (US)",
volume = "73",
pages = "381--390",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - CD7+, CD4-, CD8- acute leukemia

T2 - A syndrome of malignant pluripotent lymphohematopoietic cells

AU - Kurtzberg, J.

AU - Waldmann, T. A.

AU - Davey, Michael

AU - Bigner, S. H.

AU - Moore, J. O.

AU - Hershfield, M. S.

AU - Haynes, B. F.

PY - 1989

Y1 - 1989

N2 - Following our initial observation of in vivo conversion of CD7+, CD4-, CD8- acute lymphoblastic leukemia (ALL) cells from lymphoid to myeloid lineages (Proc Natl Acad Sci (USA) 81:253, 1984) we have studied eight additional cases of ALL with this leukemic cell phenotype. The CD7+, CD4-, CD8- phenotype was associated with a distinct clinical entity with those affected predominately male (either 65 years of age), with frequent mediastinal and/or thymic masses, skin and CNS disease, high peripheral WBC counts, and bone marrow blasts that were morphologically L1 or not ascribable to a specific lineage. These patients did not respond to conventional chemotherapeutic regimens for either acute lymphoid or myeloid leukemias. No common karyotype or T-cell gene rearrangement pattern could be defined. Importantly, seven of eight patients' leukemic cells studied were capable of multilineage (myeloid, erythroid, monocytoid, megakaryocytoid, and lymphoid) differentiation in vitro. Data is presented suggesting that CD7+, CD4-, CD8- leukemias, in many instances, are leukemias of immature hematopoietic cells. The development of novel therapeutic approaches to this form of leukemia will be necessary to alter its poor prognosis.

AB - Following our initial observation of in vivo conversion of CD7+, CD4-, CD8- acute lymphoblastic leukemia (ALL) cells from lymphoid to myeloid lineages (Proc Natl Acad Sci (USA) 81:253, 1984) we have studied eight additional cases of ALL with this leukemic cell phenotype. The CD7+, CD4-, CD8- phenotype was associated with a distinct clinical entity with those affected predominately male (either 65 years of age), with frequent mediastinal and/or thymic masses, skin and CNS disease, high peripheral WBC counts, and bone marrow blasts that were morphologically L1 or not ascribable to a specific lineage. These patients did not respond to conventional chemotherapeutic regimens for either acute lymphoid or myeloid leukemias. No common karyotype or T-cell gene rearrangement pattern could be defined. Importantly, seven of eight patients' leukemic cells studied were capable of multilineage (myeloid, erythroid, monocytoid, megakaryocytoid, and lymphoid) differentiation in vitro. Data is presented suggesting that CD7+, CD4-, CD8- leukemias, in many instances, are leukemias of immature hematopoietic cells. The development of novel therapeutic approaches to this form of leukemia will be necessary to alter its poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0024535795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024535795&partnerID=8YFLogxK

M3 - Article

C2 - 2783859

AN - SCOPUS:0024535795

VL - 73

SP - 381

EP - 390

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -